IMGN
Price:
$31.235
Market Cap:
$8.73B
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeut...[Read more]
Industry
Biotechnology
IPO Date
1989-11-17
Stock Exchange
NASDAQ
Ticker
IMGN
According to ImmunoGen, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -111.55. This represents a change of 67.17% compared to the average of -66.73 of the last 4 quarters.
The mean historical PE Ratio of ImmunoGen, Inc. over the last ten years is -8.54. The current -111.55 PE Ratio has changed 130.46% with respect to the historical average. Over the past ten years (40 quarters), IMGN's PE Ratio was at its highest in in the December 2013 quarter at 83.95. The PE Ratio was at its lowest in in the June 2023 quarter at -292.56.
Average
-8.54
Median
-6.38
Minimum
-20.37
Maximum
-1.13
Discovering the peaks and valleys of ImmunoGen, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 477.69%
Maximum Annual PE Ratio = -1.13
Minimum Annual Increase = -90.85%
Minimum Annual PE Ratio = -20.37
Year | PE Ratio | Change |
---|---|---|
2022 | -5.64 | -33.15% |
2021 | -8.44 | -50.45% |
2020 | -17.04 | 174.49% |
2019 | -6.21 | 55.13% |
2018 | -4.00 | -38.88% |
2017 | -6.55 | 477.69% |
2016 | -1.13 | -39.22% |
2016 | -1.86 | -90.85% |
2015 | -20.37 | 43.51% |
2014 | -14.19 | -28.48% |
The current PE Ratio of ImmunoGen, Inc. (IMGN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-10.37
5-year avg
-8.27
10-year avg
-8.54
ImmunoGen, Inc.’s PE Ratio is less than Madrigal Pharmaceuticals, Inc. (-10.23), less than Intercept Pharmaceuticals, Inc. (-13.55), less than TG Therapeutics, Inc. (33.32), less than Terns Pharmaceuticals, Inc. (-6.06), less than Hepion Pharmaceuticals, Inc. (-0.15), less than Viking Therapeutics, Inc. (-61.76), less than Axsome Therapeutics, Inc. (-14.37), less than Seres Therapeutics, Inc. (-0.89), less than Mereo BioPharma Group plc (-18.18), less than PDS Biotechnology Corporation (-2.64), less than Inozyme Pharma, Inc. (-3.48), less than HOOKIPA Pharma Inc. (-1.22), less than eFFECTOR Therapeutics, Inc. (-0.00), less than X4 Pharmaceuticals, Inc. (7.41), less than Elevation Oncology, Inc. (-0.93), less than Akero Therapeutics, Inc. (-8.95), less than Reata Pharmaceuticals, Inc. (-89.36),
Company | PE Ratio | Market cap |
---|---|---|
-10.23 | $5.30B | |
-13.55 | $794.69M | |
33.32 | $3.41B | |
-6.06 | $549.60M | |
-0.15 | $4.20M | |
-61.76 | $6.00B | |
-14.37 | $4.47B | |
-0.89 | $145.36M | |
-18.18 | $664.26M | |
-2.64 | $107.88M | |
-3.48 | $312.42M | |
-1.22 | $159.50M | |
-0.00 | $188.18K | |
7.41 | $109.78M | |
-0.93 | $36.94M | |
-8.95 | $1.83B | |
-89.36 | $6.57B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ImmunoGen, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ImmunoGen, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is ImmunoGen, Inc.'s PE Ratio?
How is the PE Ratio calculated for ImmunoGen, Inc. (IMGN)?
What is the highest PE Ratio for ImmunoGen, Inc. (IMGN)?
What is the 3-year average PE Ratio for ImmunoGen, Inc. (IMGN)?
What is the 5-year average PE Ratio for ImmunoGen, Inc. (IMGN)?
How does the current PE Ratio for ImmunoGen, Inc. (IMGN) compare to its historical average?